Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk 
UPS and Teamsters Reach Agreement to Limit Driver Severance Program 
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding? 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
LG Electronics Posts Record Q1 Revenue Amid Strong Demand and Cost Improvements 
Deere & Company Agrees to $99 Million Settlement Over Right-to-Repair Dispute 
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire 
Paramount Skydance Secures $24B from Gulf Sovereign Wealth Funds for Warner Bros. Discovery Takeover 
Samsung Electronics Posts Eightfold Profit Surge Driven by AI Chip Demand 
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
U.S. Automakers Push Back Against EU Rules Blocking American Trucks from European Market 
First Western Ship Transits Strait of Hormuz Since Iran War Began 
Britain Courts Anthropic Amid US Defense Department Dispute 
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation 
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions 
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis 
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown 
NEW YORK, Jan. 26, 2017 -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired securities of PixarBio Corporation (OTC MKTS:PXRB) (1) pursuant and/or traceable to PixarBio’s private placement that closed on October 30, 2016; and/or (2) publicly traded on the open market from October 31, 2016 through January 20, 2017.
You are hereby notified that a securities class action lawsuit has been commenced in the USDC for the District of New Jersey. To get more information go to:
http://www.zlk.com/pslra/pixarbio-corporation
or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.
The complaint alleges that PixarBio made false and/or misleading statements and/or failed to disclose that: (1) the market for PixarBio’s securities exhibited manipulative or deceptive activities; (2) certain assertions in press releases, third party promotional materials, and PixarBio’s Form S-1 lacked accuracy; and (3) as a result, the Company’s public statements were materially false and misleading.
On January 23, 2017, the Securities and Exchange Commission announced the temporary suspension of PixarBio trading stating, in part, that “the market for the security appears to reflect manipulative or deceptive activities and because of questions regarding the accuracy of assertions by PixarBio in press releases and its Form S-1.”
If you suffered a loss in PixarBio you have until March 27, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Levi & Korsinsky, LLP Joseph E. Levi, Esq. 30 Broad Street - 24th Floor New York, NY 10004 Tel: (212) 363-7500 Toll Free: (877) 363-5972 Fax: (212) 363-7171 www.zlk.com
